New drug camoteskimab tested for Tough-to-Treat eczema
Disease control
Completed
This study tested a new drug, camoteskimab, in 62 adults with moderate to severe eczema (atopic dermatitis). Participants received either the drug or a placebo for 16 weeks, followed by an open-label extension where everyone could get the drug. The main goal was to see if camotes…
Phase: PHASE2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Jun 26, 2026 17:44 UTC